CRL Stock Recent News
CRL LATEST HEADLINES
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules first-quarter 2025 earnings release and conference call.
Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Aldeyra Therapeutics' stock plummeted 74% due to an FDA Complete Response Letter for reproxalap but presents a favorable risk-reward for speculative investors. Despite past setbacks, ALDX's history of resilience and upcoming trial results offer potential catalysts for recovery, with minimal near-term dilution risk. ALDX's strong cash position and reduced burn rate provide a safety net, with significant upside potential if reproxalap trials succeed and FDA approval is achieved.
Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica.
WILMINGTON, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Valo Health announce the identification of an advanceable product candidate for treatment of lupus and other autoimmune diseases.
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
PORTO, Portugal & SAN FRANCISCO--(BUSINESS WIRE)--FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced that it had completed the acquisition of the South San Francisco site from Charles River Laboratories International, Inc. The acquisition aligns with FairJourney's ongoing strategic growth plan, and will significantly bolster the Company's antibody discovery and engineering capabilities, strengthening its technology portfolio and expanding its gl.
Examine the evolution of Charles River's (CRL) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.